Biomarker Testing for Autoimmune Rheumatic Disease
Customize your policy alerts
Sign up for Blue Cross Blue Shield - New Mexico Policy RPLAB011 alerts
Get alerted when Policy RPLAB011 changes without checking for updates manually.
Monitor payer policy activity
Reimbursement criteria for laboratory biomarker testing used to diagnose, evaluate, or monitor autoimmune rheumatic diseases for Blue Cross Blue Shield - New Mexico members and participating providers.
Document updated with literature review and Reimbursement Information edits; items #11, #12, #13 were edited for clarity and 'Tissue Specific Markers for Early Diagnosis of Sjögren's Disease' was added to #13.
Reimbursement Information edited for clarity on allowed frequency of biomarker testing and new non-reimbursable items added (e.g., Seronegative Rheumatoid Arthritis Profile; aisle® DX Disease Activity Index; Early Sjögren's Syndrome Profile).
Statement added: for individuals with painful and swollen joints and clinical suspicion of RA, testing for RF and/or anti-CCP may be reimbursable once per lifetime in individuals with stable symptoms; repeat testing only if significant change occurs.
Policy clarified that serum biomarker panel testing for RA disease management (e.g., Vectra DA, PrismRA) is not reimbursable; prior related policy CPCPLAB039 addressed Vectra DA.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.